SG11201803768WA - Methods and compositions for preventing or treating cancer - Google Patents
Methods and compositions for preventing or treating cancerInfo
- Publication number
- SG11201803768WA SG11201803768WA SG11201803768WA SG11201803768WA SG11201803768WA SG 11201803768W A SG11201803768W A SG 11201803768WA SG 11201803768W A SG11201803768W A SG 11201803768WA SG 11201803768W A SG11201803768W A SG 11201803768WA SG 11201803768W A SG11201803768W A SG 11201803768WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- utah
- technion
- compositions
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000406668 Loxodonta cyclotis Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1111111101111011101010111110101111111110111010101111101111101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 13 April 2017 (13.04.2017) WI P0 I P CT WO 2017/062726 Al (51) International Patent Classification: (74) Agents: LANGER, Michael et al.; 180 N. Stetson Ave., A61K 45/06 (2006.01) A61L 29/16 (2006.01) Suite 2000, Chicago, Illinois 60601 (US). A61K 48/00 (2006.01) A61L 31/16 (2006.01) A61K 38/17 (2006.01) C07K 14/47 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, PCT/US2016/055921 BZ, DO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, 7 October 2016 (07.10.2016) KW, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (25) Filing Language: English MG, OM, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (30) Priority Data: TN, 62/239,103 8 October 2015 (08.10.2015) US ZW. TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 62/379,179 24 August 2016 (24.08.2016) US (84) Designated States (unless otherwise indicated, for every (71) Applicants: UNIVERSITY OF UTAH RESEARCH kind FOUNDATION [US/US]; 615 Arapeen Drive, Suite #310, GM, Salt Lake City, Utah 84108 (US). TECHNION RE- TZ, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, SEARCH & DEVELOPMENT FOUNDATION LIM- TJ, ITED [IL/IL]; Malat Building, Floor no. 5, Technion City, DK, 3200004 Haifa (IL). LV, SM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — _ (72) Inventors: SCHIFFMAN, Joshua; 1387 S. Ambassador GW, KM, ML, MR, NE, SN, TD, TG). Way, Salt Lake City, Utah 84108 (US). SCHROEDER, Avi; Technion - Israel Institute of Technology, Room: 351, Published: 32000 Haifa (IL). ABEGGLEN, Lisa; 862 East 600 — with international search report (Art. 21(3)) South, Salt Lake City, Utah 84102 (US). = [Continued on next page] = (54) Title: METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CANCER = = = = Figure I = = = = = _ 11 ei ei 0 IN 1-1 (57) : The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid se - 0 quences encoding elephant p53 or elephant p53 amino acid sequences. ei 0 WO 2017/062726 Al IMIOHOMMIDIIM01011110111010MOHEMOVOIS — before the expiration of the time limit for amending the — with sequence listing part of description (Rule 5.2(a)) claims and amendments to be (Rule republished 48.2(h)) in the event of receipt of
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239103P | 2015-10-08 | 2015-10-08 | |
| US201662379179P | 2016-08-24 | 2016-08-24 | |
| PCT/US2016/055921 WO2017062726A1 (en) | 2015-10-08 | 2016-10-07 | Methods and compositions for preventing or treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803768WA true SG11201803768WA (en) | 2018-06-28 |
Family
ID=58488561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803768WA SG11201803768WA (en) | 2015-10-08 | 2016-10-07 | Methods and compositions for preventing or treating cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10709761B2 (en) |
| EP (1) | EP3359197B1 (en) |
| JP (1) | JP6599566B2 (en) |
| KR (1) | KR102304533B1 (en) |
| CN (1) | CN109069644B (en) |
| AU (1) | AU2016335701B2 (en) |
| BR (1) | BR112018007173B1 (en) |
| CA (1) | CA3001054C (en) |
| ES (1) | ES2863773T3 (en) |
| IL (1) | IL258512B (en) |
| MX (1) | MX2018004187A (en) |
| RU (1) | RU2718499C2 (en) |
| SG (1) | SG11201803768WA (en) |
| WO (1) | WO2017062726A1 (en) |
| ZA (1) | ZA201802268B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11788146B2 (en) * | 2017-07-06 | 2023-10-17 | Barcode Diagnostics Ltd. | Methods for therapeutics prescreening in bodily fluids |
| WO2020234871A1 (en) * | 2019-05-20 | 2020-11-26 | Technion Research & Development Foundation Limited | Metabolite encapsulating nanoparticles to enhance cellular cancer immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
| AU759164C (en) * | 1997-11-19 | 2007-03-29 | Georgetown University | Targeted liposome gene delivery |
| US6831155B2 (en) * | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| US20100143358A1 (en) | 2007-01-22 | 2010-06-10 | The United States Government As Represented By The Department Of Veterans Affairs | Use of Antibody Conjugates |
| WO2009009587A2 (en) | 2007-07-09 | 2009-01-15 | Board Of Regents Of The University Of Nebraska | Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same |
| WO2009090049A1 (en) * | 2008-01-14 | 2009-07-23 | European Molecular Biology Laboratory | Peptides for the specific binding and regulation of protein targets |
| WO2009125607A1 (en) * | 2008-04-11 | 2009-10-15 | Sapporo Medical University | Apoptosis inducer |
| CN104039343A (en) * | 2011-06-06 | 2014-09-10 | 罗得岛州妇婴医院 | He4 based therapy for malignant disease |
| CN104208066B (en) * | 2013-06-03 | 2016-06-15 | 中国科学院遗传与发育生物学研究所 | Bridged piperazine derivatives is as the purposes of p53 molecular regulation agent |
-
2016
- 2016-10-07 US US15/767,099 patent/US10709761B2/en active Active
- 2016-10-07 SG SG11201803768WA patent/SG11201803768WA/en unknown
- 2016-10-07 JP JP2018538063A patent/JP6599566B2/en active Active
- 2016-10-07 BR BR112018007173-0A patent/BR112018007173B1/en active IP Right Grant
- 2016-10-07 CA CA3001054A patent/CA3001054C/en active Active
- 2016-10-07 KR KR1020187012840A patent/KR102304533B1/en active IP Right Grant
- 2016-10-07 EP EP16854394.0A patent/EP3359197B1/en active Active
- 2016-10-07 AU AU2016335701A patent/AU2016335701B2/en active Active
- 2016-10-07 CN CN201680066779.4A patent/CN109069644B/en active Active
- 2016-10-07 MX MX2018004187A patent/MX2018004187A/en unknown
- 2016-10-07 RU RU2018116896A patent/RU2718499C2/en active
- 2016-10-07 WO PCT/US2016/055921 patent/WO2017062726A1/en active Application Filing
- 2016-10-07 ES ES16854394T patent/ES2863773T3/en active Active
-
2018
- 2018-04-05 IL IL258512A patent/IL258512B/en unknown
- 2018-04-06 ZA ZA2018/02268A patent/ZA201802268B/en unknown
-
2020
- 2020-06-05 US US16/894,698 patent/US11833188B2/en active Active
-
2023
- 2023-10-03 US US18/480,362 patent/US20240016890A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL258512A (en) | 2018-05-31 |
| RU2718499C2 (en) | 2020-04-08 |
| AU2016335701A1 (en) | 2018-05-10 |
| KR20180086188A (en) | 2018-07-30 |
| CA3001054A1 (en) | 2017-04-13 |
| IL258512B (en) | 2021-07-29 |
| US20240016890A1 (en) | 2024-01-18 |
| CN109069644A (en) | 2018-12-21 |
| CA3001054C (en) | 2021-12-14 |
| EP3359197A1 (en) | 2018-08-15 |
| JP2018534357A (en) | 2018-11-22 |
| WO2017062726A1 (en) | 2017-04-13 |
| US11833188B2 (en) | 2023-12-05 |
| US10709761B2 (en) | 2020-07-14 |
| US20190070259A1 (en) | 2019-03-07 |
| AU2016335701B2 (en) | 2019-03-07 |
| JP6599566B2 (en) | 2019-10-30 |
| ES2863773T3 (en) | 2021-10-11 |
| BR112018007173B1 (en) | 2021-02-02 |
| EP3359197A4 (en) | 2019-04-10 |
| MX2018004187A (en) | 2019-01-21 |
| KR102304533B1 (en) | 2021-09-28 |
| CN109069644B (en) | 2022-10-28 |
| US20200368316A1 (en) | 2020-11-26 |
| RU2018116896A3 (en) | 2019-11-11 |
| BR112018007173A2 (en) | 2018-10-16 |
| EP3359197B1 (en) | 2021-03-10 |
| ZA201802268B (en) | 2019-01-30 |
| RU2018116896A (en) | 2019-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201804807VA (en) | Computer architecture and method for modifying data intake parameters based on a predictive model | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201909495PA (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201811345TA (en) | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
| SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |